ezgif.com-gif-maker.png
Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM Microbe 2019
27 juin 2019 08h00 HE | Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
L’activité exception
L’activité exceptionnelle du DNV3681 contre des menaces bioterroristes présentée à l’ASM Microbe 2019
24 juin 2019 12h00 HE | Deinove
L’activité exceptionnelle du DNV3681 contre des menaces bioterroristes présentée à l’ASM Microbe 2019 Le Major Steven Zumbrun (USAMRIID1, Département de la Défense des Etats-Unis) a présenté la...
DNV3681's exceptiona
DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019
24 juin 2019 12h00 HE | Deinove
DNV3681's exceptional activity against bioterrorist threats presented at ASM Microbe 2019 Major Steven Zumbrun (USAMRIID1, U.S. Department of Defense) presented data on the in vitro assessment of...
ezgif.com-gif-maker.png
Entasis Therapeutics Announces Oral and Poster Presentations of its Pathogen-Targeted Antibiotic Clinical Programs at ASM Microbe 2019
10 juin 2019 08h00 HE | Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...